Cargando…
Intracellular Levels of Two Cyclosporin Derivatives Valspodar (PSC 833) and Cyclosporin A Closely Associated with Multidrug Resistance‐modulating Activity in Sublines of Human Colorectal Adenocarcinoma HCT‐15
P‐Glycoprotein, which mediates multidrug resistance (MDR) in cancer chemotherapy, is a principal target of Cyclosporin A and [3′‐keto‐Bmt(1)]‐[Val(2)]‐cyclosporin (valspodar; PSC 833). To clarify mechanisms contributing to the different MDR‐modulating activities of valspodar and Cyclosporin A, we in...
Autores principales: | Uchiyama‐Kokubu, Noriko, Watanabe, Toru, Cohen, Dalia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926616/ https://www.ncbi.nlm.nih.gov/pubmed/11676863 http://dx.doi.org/10.1111/j.1349-7006.2001.tb01067.x |
Ejemplares similares
-
Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
por: Lehne, G., et al.
Publicado: (1998) -
Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
por: Minami, Hironobu, et al.
Publicado: (2001) -
Modulation of Multidrug Resistance by SDZ PSC 833 in Leukemic and Solid‐tumor‐bearing Mouse Models
por: Watanabe, Toru, et al.
Publicado: (1996) -
Inhibitory Effects of a Cyclosporin Derivative, SDZ PSC 833, on Transport of Doxorubicin and Vinblastine via Human P‐Glycoprotein
por: Kusunoki, Nobuya, et al.
Publicado: (1998) -
Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats
por: Rowbottom, Christopher, et al.
Publicado: (2021)